Methods and Compounds Useful to Induce Apoptosis in Cancer Cells
AssigneeSanford-Burnham Medical Research Institute
InventorsJohn C. Reed, Maurizio Pellecchia
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
Claims24
A method of treating cancer in a subject, comprising administering to the subject a chemosensitizing agent selected from the group consisting of gossypol, apogossypol, derivatives of apogossypol, theaflavin, theaflavin-3′-gallate, theaflavanin, (−) gallocatechin-3-gallate (GCG), (−) epigallocatechin-3-gallate (EGCG), (−) catechin-3-gallate (CG), (−) epicatechin-3-gallate (ECG), derivatives of purpurogallin, and mixtures thereof, in combination with an anticancer agent.
A method for inducing apoptosis, modulating caspase activity, or inducing cell death in a mammal comprising contacting target cells with a compound having the formula (I)
- wherein:
- each R6, R8, R9, and R10 are independently hydrogen, hydroxyl, —(C1-C6)alkyl, —O(C1-C6)alkyl, —(C1-C6)alkylhalo, —OC(O)(C1-C6)alkyl, or halo;
- each R7 is independently hydrogen, —(C3-C8)cycloalkyl, —(C6-C10)aryl, or —(C1-C6)alkyl(C6-C10)aryl;
- or a pharmaceutically acceptable salt thereof, effective to induce apoptosis, modulate caspase activity, or induce cell death the target cells.
A method of identifying an agent that inhibits the anti-apoptotic activity of the Bcl-2 family proteins comprising:
- (a) identifying a Bcl-2 inhibitor or a labeled Bcl-2 inhibitor, wherein the inhibitor is selected from the group consisting of gossypol, apogossypol, derivatives of apogossypol, theaflavin, theaflavin-3′-gallate, theaflavanin, (−) gallocatechin-3-gallate (GCG), (−) epigallocatechin-3-gallate (EGCG), (−) catechin-3-gallate (CG), (−) epicatechin-3-gallate (ECG), and derivatives of purpurogallin;
- (b) contacting the bound inhibitor with a candidate agent, said candidate agent suspected of being able to inhibit the Bcl-2 family proteins;
- and
- (c) detecting dissociation of the inhibitor from the Bcl-2 family protein, whereby the agent is identified as an agent that inhibits Bcl-2 family proteins.
Dependencies are inferred from the claim text.